Clinical Trial Update: Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) [Phase 2]

View source ↗

Summary

Phase 2 trial of ISIS 678354 (AKCEA-APOCIII-LRx) in participants with hypertriglyceridemia and established cardiovascular disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Hypertriglyceridemia

Drugs mentioned

• ISIS 678354 (AKCEA-APOCIII-LRx)

Snippet

Sponsor: Akcea Therapeutics | Conditions: Hypertriglyceridemia, Cardiovascular Diseases | Phase 2 | Status: COMPLETED | Results posted: 2023-01-11